Patents and Covid-19 vaccines: the recipe isn’t everything you need Esade

Since last winter, vaccines have become the backbone of most of the developed countries fight against the Covid-19 pandemic. After a record-breaking development by a handful of companies backed by governments and it’s approval by regulators, the administration has paced up rapidly and by the second half of this year, most of Europeans and North-Americans are expected to be vaccinated.

However, most of the developing countries are still waiting for significant amounts of doses, leading the United States to propose waving patent rights for Covid vaccines in order to ease its production. George Chondrakis, associate professor of strategic management at Esade Business School, discusses with Carlos Serrano, associate professor of economics and business at Universitat Pompeu Fabra, on intellectual property rights and its role in boosting vaccines supply around the world.

Hosted by Ausha. See ausha.co/privacy-policy for more information.